Biogen Inc. (NASDAQ: BIIB), a leading biotechnology company, has released its Q1 2024 financial results, showcasing ...

Biogen maintained its 2024 adjusted EPS guidance of $15 to $16, compared with the Capital IQ-polled consensus of $15.48. The company continues to expect a a low- to mid-single digit drop in revenue as ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Biogen Inc. (BIIB) reports results for the quarter ended March 2024. While this widely-known consensus outlook is ...

Biogen (NASDAQ:BIIB) on Wednesday reported first-quarter profit that topped estimates as the company's cost-cutting efforts ...

Biogen (NASDAQ:BIIB) reported its first quarter 2024 earnings, surpassing expectations for adjusted earnings per share (EPS) ...

Besides Wall Street's top -and-bottom-line estimates for Biogen (BIIB), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research ...

Drugmaker Biogen (BIIB.O) gained 4.5 per cent after it beat first-quarter ... compared with the 11.07 billion average for the ...

Nasdaq and S&P 500 futures signaled a higher open on Wednesday, thanks to upbeat guidance from EV giant Tesla, Inc.

Wall Street on Wednesday recovered some of its losses, as a slump in industrials and a surge in Treasury yields grappled with ...